Search Results 601-610 of 16255 for pharmacogenetics
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
The purpose of this study is to determine if the use of Gilenya® can reduce neuropathy caused by paclitaxel. Participation eligibility. Participant eligibility ...
The purpose of this study is to assess the impact of pharmacist consultation in patients receiving first dose, first cycle intravenous cancer treatment on ...
Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure, one of the world's most[...] ...
About this study. Pazopanib is FDA approved as a second line and beyond treatment for metastatic soft tissue sarcoma. There is a population of elderly and ...
Amid baby babble, Jordyn LaMont's eyes grow wide with excitement as she spots her father, Brandon LaMont, and he bursts into a wide smile, playfully raising ...
Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms. Leuk Lymphoma. 2025 Mar; 66(3):497-506. Epub 2024 Nov 06. View PubMed; Gao RW, ...
About this study. The purpose of this study is to perform studies to identify mutations in ACTA2, MYH11, and potentially other genes in individuals with ...
The long-term goal of this study is to alleviate the occurrence of CIN and fatigue and to improve chemotherapy treatment outcomes. The identification of ...
Mayo Clinic Clinical Genomics uses genomic testing to develop knowledge about a person's DNA to help predict, prevent, diagnose and treat disease.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.